Huahai zoom in! 9 new drugs, 12 new products on the road, 22 over-rated varieties "play around" set, performance exceeded expectations

Recently, Huahai Pharmaceuticals 2 category 1 new drugs have been approved clinically, the third quarter reported a 60%-70% increase in net profit.
this year, Huahai pharmaceutical industry has been approved 7 varieties listed, 3 new class 1 drugs approved clinically.
the current Huahai pharmaceutical industry has 22 varieties over-evaluation (14 for the first), 12 varieties of the winning collection.
volume procurement makes Huahai Pharmaceuticals stand out among a group of generic pharmaceutical companies, but the company is not in love with the war, innovative drugs, biopharmaceuticals business has been steadily advancing.
there are currently 14 new drugs to be developed by Huahai drug owners, of which 9 are in class 1 new drugs.
14 new drugs bright eyes, 1 class of new drugs have come recently, Huahai Pharmaceuticals announced that two new drugs of class 1 HOT-1030 injection, HB002.1M (3 new adaptive disorders) have been approved clinically.
this year, Huahai Pharmaceuticals has approved three new class 1 drugs, namely HB002.1M, HOT-1030 injection, HB0017 injection.
m. intranet data show that there are currently 14 new drugs to be developed by Huahai drug owners, including small molecule innovative drugs and biological drugs.
from the drug type, there are 8 chemicals and 6 therapeutic biological products.
from the registration classification, there are nine new class 1 drugs.
HB0017 is an innovative drug for both China and the United States.
Huahai pharmaceutical owners to research innovative drugs Source: Mi Net database, the company announced small molecules innovative drugs, Huahai Pharmaceuticals HHT-101 and HHT-201 are nervous system drugs.
HT-101 (hydroxyhydroxyptonide hydrochloride hydrochloride tablets) for the treatment of depression drugs, has completed phase II clinical trials, HHT-201 (injection with hydroxybenzone Donnelly) for the treatment of Alzheimer's disease drugs, Phase I clinical trials in the process.
addition, the company has a number of small molecules in the study of new drugs.
Biopharmaceuticals, Huahai Pharmaceuticals focused on tumor, immunotherapy and other fields, two biosynthetic drugs HOT-3010 (recombinant all-human source anti-tumor necrotic cause -α monoclonal antibody injection), HOT-1010 (recombinant anti-VEGF human-derived monoclonal antibody injection) has completed Phase I clinical trials, is expected to be launched in late 2022 and early 2023.
class 1 biopharmaceuticals, HB002.1M (recombinant VEGFR-Fc fusion protein eye injection) the first adaptive disorder (wet age-related macular degeneration) has entered Phase II clinical trials, is expected to be launched in early 2024, HB002.1T has started Phase I clinical trials; The HB0017 injection is a monoclonal antibody with white mesolytin-17 (IL-17) as its target, and three adaptations are approved clinically;
12 new products on the road, deep cultivation of two hundred billion market generics, this year, Huahai Pharmaceuticals has 7 varieties (16 regulations) approved for listing, all with the new registration classification of production, approved and regarded as passing a consistent evaluation.
to date, Huahai Pharmaceuticals has 12 varieties (24 acceptance numbers) of generic drugs reported in the new classification reviewed, and will be treated as if they had been approved for production.
among them, otoxyfluoxetine capsules and topiracester tablets were not approved for listing in the domestic market, and four varieties were included in the priority review, namely Devasalban tablets, timishatan tablets, temishatan hydrochlorochloride tablets, and pyridoxine tablets.
Huahai Pharmaceuticals in the review of the new registered classification of generic drugs Source: Minet MED2.0 China Drug Review Database From the treatment category, Huahai Pharmaceuticals in the review of generic drugs mainly layout cardiovascular, mental nerve and other therapeutic fields.
, there are 4 varieties of drugs acting on the renin-angiotrophic system, 3 varieties of psychostation drugs, 2 varieties of anti-epileptic drugs and anti-thrombosis drugs. according to
meters of intranet data, in 2019 China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (China's public medical institutions) terminal cardiovascular system drugs, neurological drugs sales of more than 100 billion yuan.
22 over-rated varieties "play around" set, performance all the way up so far, Huahai Pharmaceuticals has 22 varieties (40 product rules) through / as if through the consistency evaluation.
22 over-rated varieties were nervous system drugs, cardiovascular drugs, and systemic anti-infectant drugs.
from the evaluation order, Huahai Pharmaceuticals 22 varieties of 14 for the first review.
, five varieties, such as aliphenidate tablets, lamotrigine tablets, renopri tablets, Fosinple sodium tablets, and nevela flat tablets, were reviewed exclusively.
Huahai Pharmaceuticals through / as if through the consistent evaluation of varieties Source: MED2.0 China Pharmaceutical Review Database as a domestic specialty API and generic drug export pioneers, Huahai Pharmaceuticals has intermediates, API, preparations vertical integration of the complete industrial chain advantages, so the company in 2018 at the beginning of the national harvest has attracted much attention from the industry.
three batches carried out in the country, Huahai Pharmaceuticals won 7, 2 and 3 varieties respectively, with a total of 12 varieties winning the bid.
the national drug belt procurement huahai pharmaceutical industry in the selection of the situation with volume procurement so that Huahai pharmaceutical industry in the domestic group of generic pharmaceutical companies stand out.
from the performance of Huahai Pharmaceutical Industry, the collection of winning bid to help the company's products quickly open the market, market share increased, profit increased.
the third quarter report of Huahai Pharmaceuticals, net profit is expected to be RMB820 million to RMB870 million in January-September 2020, up about 60%-70% YoY.
increase in domestic production performance was mainly due to a significant increase in sales of domestic preparations and API.
In the short term, Huahai Pharmaceuticals is the big winner of the national harvest, but with the normalization of collection and drug prices repeatedly low, the collection of no eternal winners, the future may be full of thorns.
, in recent years, Huahai Pharmaceuticals has continuously improved its research and development innovation capabilities and accelerated the development of biopharmaceity and new drugs.
market space for biopharmaceons and new drugs, the future will become the company's new profit growth point.